RxDoctor Payments DataLook up a doctor →

Marissa Torres, NP

Nurse Practitioner · Atlanta, GANPI 1285199794

Payments from drug & device makers

$11,709in general payments, 2019–2025

Across 547 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$792
  • Biogen$585
  • Neurelis, Inc.$467
  • SK Life Science, Inc.$406
  • Lilly USA, LLC$398
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)105$1,976
UCB, Inc.31$792
Biogen30$585
Neurelis, Inc.24$467
SK Life Science, Inc.15$406
Lilly USA, LLC21$398
Pfizer17$375
Neurocrine Biosciences, Inc.14$352
Axsome Therapeutics, Inc.14$322
Alnylam Pharmaceuticals Inc.13$320
MDD US Operations, LLC6$319
Lundbeck LLC12$307
Otsuka America Pharmaceutical, Inc.12$302
Teva Pharmaceuticals USA, Inc.13$265
Biohaven Pharmaceuticals, Inc.11$241
Scilex Pharmaceuticals Inc.12$240
Kyowa Kirin, Inc.12$221
Jazz Pharmaceuticals Inc.9$215
Catalyst Pharmaceuticals, Inc.8$189
EMD Serono, Inc.10$183
Harmony Biosciences LLC9$180
Acadia Pharmaceuticals Inc10$176
Argenx US, Inc.7$172
Acorda Therapeutics, Inc9$172
Amneal Pharmaceuticals LLC8$169
Arbor Pharmaceuticals, Inc.8$142
Novartis8$138
Upsher-smith Laboratories LLC7$129
Biohaven Pharmaceutical Holding Company Ltd.7$128
Genentech USA, Inc.6$120
Johnson & Johnson(2 entities)5$106
Sanofi-aventis U.S. LLC5$103
Vanda Pharmaceuticals Inc.3$84
Takeda Pharmaceuticals U.S.A., Inc.3$84
Azurity Pharmaceuticals, Inc.4$81
Eisai Inc.4$80
Grifols USA, LLC3$80
Avanir Pharmaceuticals, Inc.4$75
Sanofi3$74
Bristol Myers Squibb3$72
ANI Pharmaceuticals, Inc.3$70
Merz Pharmaceuticals, LLC3$68
Sumitomo Pharma America, Inc.3$68
Sunovion Pharmaceuticals Inc.4$66
Impel Pharmaceuticals Inc.3$53
CSL Behring2$52
AstraZeneca3$49
Merck2$43
Corium, LLC2$43
Spectrum Pharmaceuticals Inc.2$42
Almatica Pharma LLC2$34
GE HealthCare1$33
Otter Pharmaceuticals, LLC1$30
Springworks Therapeutics, Inc.1$29
Supernus Pharmaceuticals, Inc.1$24
Idorsia Pharmaceuticals US Inc1$23
Akcea Therapeutics, Inc.1$21
Adamas Pharmaceuticals, Inc.1$21
Forte Bio-pharma LLC1$20
Aquestive Therapeutics, Inc.1$19

How this compares

$11,709 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$37,591
Medicare patients
105
Services billed
1,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →